Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Citi initiated coverage of Moderna (MRNA) with a Neutral rating and $40 price target Healthcare policy remains a key biopharma sector ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S.

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...